AI-ECG Tracker vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-ECG Tracker

by Carewell Health

ElucidVivo A.3

by Elucid

AI Verdict

These tools are adjacent in the broader field of Cardiology AI, but serve distinct diagnostic purposes. AI-ECG Tracker focuses on rapid AI-powered analysis of ECG data for cardiac abnormalities, while ElucidVivo A.3 provides quantitative analysis of arterial plaque composition from CT angiography for atherosclerosis patient stratification. Physicians would likely utilize both for different aspects of cardiovascular patient care rather than choosing one over the other.

Choose AI-ECG Tracker if…

Choose AI-ECG Tracker if your primary need is rapid, high-accuracy AI-powered auto-diagnosis of cardiac electrical abnormalities from 12-lead ECG data. This tool is ideal for quickly identifying arrhythmias, myocardial ischemia, and other common heart conditions, providing comprehensive diagnostic support in approximately 3 seconds.

View AI-ECG Tracker →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients. This system excels at providing detailed visualization and measurement of plaque characteristics, such as Lipid-Rich Necrotic Core, to optimize treatment decisions and assess cardiovascular risk.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-ECG Tracker	ElucidVivo A.3
Deployment	Mobile app, intended for use by qualified healthcare professionals in hospitals and other healthcare facilities.	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-ECG Tracker

AI-ECG Tracker emphasizes rapid diagnosis in approximately 3 seconds and offers a web-based management portal, suggesting a streamlined and efficient workflow for high-volume ECG analysis. While ElucidVivo A.3 provides advanced 3D visualization for complex imaging, Tool A's focus on speed and a web portal points to a potentially more user-friendly experience for routine diagnostic tasks.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 offers highly specialized, quantitative analysis of arterial plaque composition and stability from CT angiography, validated against ground-truth histology. This provides deeper, more specific insights for atherosclerosis patient stratification and treatment optimization. While AI-ECG Tracker offers broad and rapid ECG diagnosis, ElucidVivo's detailed plaque characterization represents a more advanced and impactful clinical insight for its specific niche.

Pricing & Value

Tie

Both tools explicitly state that their pricing is not publicly available or requires contacting them for a quote. Without any transparent pricing information for either product, it is impossible to conduct a head-to-head comparison on this dimension. Therefore, it is a tie.

Enterprise Readiness

AI-ECG Tracker

AI-ECG Tracker, from a subsidiary of Lepu Medical, explicitly mentions a 'Web-based Management Portal for organization settings, security, and task management,' and its parent company distributes to over 100 countries, indicating robust enterprise features and global scalability. While ElucidVivo A.3 integrates with PACS/EMR, Tool A's explicit management portal and broader international presence suggest a higher degree of enterprise readiness.

Innovation

ElucidVivo A.3

ElucidVivo A.3's innovation lies in its highly specific, quantitative analysis of arterial plaque composition from CT angiography, including quantification of Lipid-Rich Necrotic Core (LRNC) and derivation of FFRct, validated against ground-truth histology. This represents a cutting-edge approach to cardiovascular risk stratification. While AI-ECG Tracker offers high accuracy and speed in ECG diagnosis, ElucidVivo's detailed, histology-validated plaque characterization pushes the boundaries of diagnostic imaging.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the level of customer support, availability of comprehensive documentation, or training resources for either AI-ECG Tracker or ElucidVivo A.3. Without this information, a meaningful comparison is not possible, resulting in a tie.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-ECG Tracker	ElucidVivo A.3
Name	AI-ECG Tracker	ElucidVivo A.3
Company	Shenzhen Carewell Electronics Co.	Elucid Bioimaging
Primary AI Focus	AI-powered ECG auto-diagnosis	AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography
Key AI Analysis Output	High accuracy (over 95%) for common cardiac abnormalities, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction; comprehensive diagnosis support for 16 cardiac classifications and 104 ECG diagnostic classifications.	Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.
Supported Specialties	Cardiology, Emergency Medicine	Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring AI-ECG Tracker and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate with existing EHR and PACS systems to streamline clinical workflow and data exchange?

AI-ECG Tracker utilizes an AI-ECG Workstation and Diagnostic Client, with an optional cloud service, suggesting integration points for ECG data management and reporting. ElucidVivo A.3 is designed as a software application that integrates with PACS/EMR, indicating a direct connection for image and report management within existing radiology and cardiology workflows.

For which specific patient populations and clinical scenarios is each tool most effective, and how does it directly inform treatment decisions?

AI-ECG Tracker is highly effective for rapid, AI-powered diagnosis of common cardiac abnormalities from 12-lead ECGs, aiding in the management of acute and chronic cardiac conditions. ElucidVivo A.3 provides quantitative analysis of arterial plaque from CT angiography, assisting in atherosclerosis patient stratification and optimizing treatment decisions based on detailed plaque characteristics.

What are the specific accuracy metrics and validation methods for each tool, particularly concerning their respective diagnostic outputs?

AI-ECG Tracker demonstrates high accuracy (over 95%) for common cardiac abnormalities, including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction. ElucidVivo A.3's quantitative plaque analysis is validated against ground-truth histology, providing objective quantification of components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications.

What is the expected learning curve for physicians and support staff to effectively utilize each tool in daily practice?

AI-ECG Tracker offers rapid diagnosis in approximately 3 seconds and comprehensive classifications, suggesting a relatively quick adoption for interpreting its automated ECG analysis. ElucidVivo A.3 involves detailed 3D visualization and quantitative analysis of plaque, which may require initial training to fully leverage its advanced features for patient stratification.

What audit-trail capabilities does each system offer to track diagnostic decisions and user interactions for compliance and quality assurance?

AI-ECG Tracker includes a Web-based Management Portal for organization settings, security, and task management, which likely incorporates features for activity logging and traceability. While not explicitly detailed, ElucidVivo A.3, as a medical image analysis system integrating with PACS/EMR, would typically include audit trails for tracking analysis, modifications, and report generation.

Beyond standard compliance, what advanced security measures are in place to protect patient data and ensure system integrity?

AI-ECG Tracker's Web-based Management Portal manages security settings, implying robust access controls and potentially other protective measures for its on-premise and cloud components. ElucidVivo A.3, by integrating with PACS/EMR, would rely on secure data transfer protocols and system-level security, though specific advanced measures are not explicitly detailed in the provided information.

What are the key considerations and requirements for deploying each tool across multiple clinical sites or a large hospital network?

AI-ECG Tracker's on-premise workstation and diagnostic client, combined with an optional cloud service, offers flexibility for multi-site deployment, potentially leveraging the cloud for remote diagnostic services. ElucidVivo A.3's integration with PACS/EMR is a critical factor for scalability across multiple sites, enabling centralized access to imaging data and analysis.